mRNA Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

The global mRNA therapeutics market was valued at USD 6.01 billion in 2025. The market is projected to grow to USD 6.85 billion in 2026 and further expand to USD 26.06 billion by 2034, exhibiting a strong CAGR of 18.18% during the forecast period (2026-2034).

North America dominated the global market in 2025, accounting for 31.47% market share, driven by robust R&D investments, favorable regulatory support, and early commercialization of mRNA-based COVID-19 vaccines.

The market has undergone rapid transformation following the success of mRNA vaccines during the COVID-19 pandemic. Leading companies such as Moderna Inc., BioNTech, Pfizer Inc., and GSK plc. are actively expanding their pipelines beyond infectious diseases into oncology and rare genetic disorders.

Additionally, the first mRNA drug (non-vaccine therapeutic) is expected to launch in 2027. The mRNA drugs/medications segment alone is projected to reach USD 2 billion by 2032, growing at an exceptional CAGR of 118.7% between 2027 and 2032.

Market Dynamics

Market Drivers

Advantages of mRNA Therapeutics

mRNA-based therapeutics offer several advantages over conventional vaccines and treatments. These include:

High efficacy in preventing severe illness
Faster development timelines
Adaptability to emerging virus strains
Favorable safety profile
Lower risk of genomic integration

The rapid response capability demonstrated during the COVID-19 pandemic significantly strengthened confidence in mRNA technology. Growing applications in infectious diseases, oncology, and rare disorders continue to drive market expansion.

Market Restraints

Storage and Stability Challenges

Despite strong demand, mRNA therapeutics require ultra-cold storage conditions, creating logistical challenges. Many low-resource countries lack adequate cold chain infrastructure, limiting widespread adoption.

High Manufacturing Costs

The large-scale production of mRNA products involves complex purification processes and advanced lipid nanoparticle (LNP) delivery systems. These factors significantly increase production costs and limit scalability.

Market Opportunities

Advancements in Drug Delivery Technologies

Ongoing innovations in delivery systems are improving mRNA stability and therapeutic effectiveness. Technologies such as:

Lipid nanoparticles (LNPs)
Polymeric nanoparticles
Cationic nanoparticles

are enhancing intracellular delivery efficiency. These advancements are expected to support commercialization of next-generation mRNA therapies, especially in oncology and rare diseases.

Market Challenges

Stringent regulatory frameworks across regions
Evolving approval pathways
Public perception and vaccine hesitancy
Infrastructure limitations in developing economies

Addressing these challenges will be essential for sustained long-term growth.

Market Trends

Growing Adoption Beyond Vaccines

While vaccines dominate the market, mRNA technology is increasingly being used for personalized cancer therapies and rare genetic conditions. Nearly 40% of mRNA clinical trials are currently in Phase I, reflecting a rapidly expanding pipeline.

Pharmaceutical companies are heavily investing in oncology-focused mRNA therapeutics, highlighting the technology's potential to revolutionize precision medicine.

Segmentation Analysis

By Type

The market is segmented into:

1. Prophylactic (Vaccines)

2. Drugs/Medications

The prophylactic segment dominated the market in 2024 and is expected to maintain leadership through 2026. In fact, the segment is projected to account for 100% of the market share in 2026, as approved mRNA products currently exist only in the vaccine category (COVID-19 and RSV vaccines).

However, the drugs/medications segment is projected to grow at the fastest rate post-2027, driven by oncology and rare disease pipelines.

By Application

Infectious Diseases (Dominant in 2024 and expected to contribute 100% share in 2026)
Oncology (Fastest growing)
Others

As of January 2025, regulatory approvals exist only for infectious disease applications, reinforcing this segment's dominance.

By Distribution Channel

Hospital Pharmacies (Largest share in 2024)
Drug Stores & Retail Pharmacies
Others

Hospital pharmacies accounted for the highest share due to professional administration requirements. The hospital & retail pharmacies segment is projected to hold 63.62% market share in 2026.

Regional Outlook

North America

North America generated USD 1.89 billion in 2025 and led the global market. The U.S. remains the dominant contributor and is estimated to reach USD 2.16 billion by 2026, supported by strong federal funding and FDA approvals.

Europe

Europe is projected to witness significant growth. Germany is expected to reach USD 0.37 billion by 2026, while the U.K. market is forecast at USD 0.15 billion in 2026.

Asia Pacific

Asia Pacific is anticipated to grow at the fastest rate. By 2026:

Japan: USD 0.63 billion
China: USD 0.58 billion
India: USD 0.27 billion

Increasing R&D investments are fueling regional expansion.

Rest of the World

Latin America and the Middle East & Africa held smaller shares in 2024 but are expected to grow steadily with improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive with key players including:

Moderna Inc.
BioNTech
Pfizer Inc.
CureVac SE
GSK plc.
Sanofi
Omega Therapeutics
Strand Therapeutics

These companies focus heavily on R&D, pipeline expansion, and strategic partnerships to strengthen their market presence.

Conclusion

The global mRNA therapeutics market is set for remarkable expansion, increasing from USD 6.01 billion in 2025 to USD 6.85 billion in 2026, and reaching USD 26.06 billion by 2034, growing at a CAGR of 18.18%. North America remains the leading region, supported by strong regulatory backing and innovation ecosystems. While vaccines currently dominate the market, the rapid emergence of mRNA-based drugs for oncology and rare diseases signals the next major growth phase. Overcoming storage, cost, and regulatory challenges will be critical to sustaining this strong upward trajectory through 2034.

Segmentation

By Type

Prophylactic (Vaccines)
- COVID-19 Vaccines
- Non-COVID-19 Vaccines
Drugs/Medications

By Application

Oncology
Infectious Diseases
Others

By Distribution Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Others

By Region

North America (By Type, Application, Distribution Channel, and Country)
- U.S.
- Canada
Europe (By Type, Application, Distribution Channel, and Country/Sub-Region)
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of the Asia Pacific
Rest of the World (By Type, Application, Distribution Channel)

Product Code: FBI113411

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Overview: Advancements in mRNA Technology
4.2. Future Growth Prospects for mRNA Therapeutics
4.3. Pipeline Analysis, By Key Players
4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
4.5. Impact of Tariff on the Market

5. Global mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Prophylactic (Vaccines)
  - 5.1.1.1. COVID-19 Vaccines
  - 5.1.1.2. Non-COVID-19 Vaccines
- 5.1.2. Drugs/Medications
5.2. Market Analysis, Insights and Forecast - By Application
- 5.2.1. Oncology
- 5.2.2. Infectious Diseases
- 5.2.3. Others
5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Drug Stores & Retail Pharmacies
- 5.3.3. Others
5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World

6. North America mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Prophylactic (Vaccines)
  - 6.1.1.1. COVID-19 Vaccines
  - 6.1.1.2. Non-COVID-19 Vaccines
- 6.1.2. Drugs/Medications
6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Oncology
- 6.2.2. Infectious Diseases
- 6.2.3. Others
6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Drug Stores & Retail Pharmacies
- 6.3.3. Others
6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada

7. Europe mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Prophylactic (Vaccines)
  - 7.1.1.1. COVID-19 Vaccines
  - 7.1.1.2. Non-COVID-19 Vaccines
- 7.1.2. Drugs/Medications
7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Oncology
- 7.2.2. Infectious Diseases
- 7.2.3. Others
7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Drug Stores & Retail Pharmacies
- 7.3.3. Others
7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Rest of Europe

8. Asia Pacific mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Prophylactic (Vaccines)
  - 8.1.1.1. COVID-19 Vaccines
  - 8.1.1.2. Non-COVID-19 Vaccines
- 8.1.2. Drugs/Medications
8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Oncology
- 8.2.2. Infectious Diseases
- 8.2.3. Others
8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Drug Stores & Retail Pharmacies
- 8.3.3. Others
8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Prophylactic (Vaccines)
  - 9.1.1.1. COVID-19 Vaccines
  - 9.1.1.2. Non-COVID-19 Vaccines
- 9.1.2. Drugs/Medications
9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Oncology
- 9.2.2. Infectious Diseases
- 9.2.3. Others
9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Drug Stores & Retail Pharmacies
- 9.3.3. Others

10. Competitive Analysis

10.1. Global Market Share Analysis (2025)
10.2. Company Profiles
- 10.2.1. Moderna Inc.
  - 10.2.1.1. Overview
  - 10.2.1.2. Products & services
  - 10.2.1.3. SWOT Analysis
  - 10.2.1.4. Recent Developments
  - 10.2.1.5. Strategies
  - 10.2.1.6. Financials (Based on Availability)
- 10.2.2. BioNTech
  - 10.2.2.1. Overview
  - 10.2.2.2. Products & services
  - 10.2.2.3. SWOT Analysis
  - 10.2.2.4. Recent Developments
  - 10.2.2.5. Strategies
  - 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Pfizer Inc.
  - 10.2.3.1. Overview
  - 10.2.3.2. Products & services
  - 10.2.3.3. SWOT Analysis
  - 10.2.3.4. Recent Developments
  - 10.2.3.5. Strategies
  - 10.2.3.6. Financials (Based on Availability)
- 10.2.4. CureVac SE
  - 10.2.4.1. Overview
  - 10.2.4.2. Products & services
  - 10.2.4.3. SWOT Analysis
  - 10.2.4.4. Recent Developments
  - 10.2.4.5. Strategies
  - 10.2.4.6. Financials (Based on Availability)
- 10.2.5. GSK plc
  - 10.2.5.1. Overview
  - 10.2.5.2. Products & services
  - 10.2.5.3. SWOT Analysis
  - 10.2.5.4. Recent Developments
  - 10.2.5.5. Strategies
  - 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Sanofi
  - 10.2.6.1. Overview
  - 10.2.6.2. Products & services
  - 10.2.6.3. SWOT Analysis
  - 10.2.6.4. Recent Developments
  - 10.2.6.5. Strategies
  - 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Omega Therapeutics
  - 10.2.7.1. Overview
  - 10.2.7.2. Products & services
  - 10.2.7.3. SWOT Analysis
  - 10.2.7.4. Recent Developments
  - 10.2.7.5. Strategies
  - 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Strand Therapeutics
  - 10.2.8.1. Overview
  - 10.2.8.2. Products & services
  - 10.2.8.3. SWOT Analysis
  - 10.2.8.4. Recent Developments
  - 10.2.8.5. Strategies
  - 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Immunomic Therapeutics
  - 10.2.9.1. Overview
  - 10.2.9.2. Products & services
  - 10.2.9.3. SWOT Analysis
  - 10.2.9.4. Recent Developments
  - 10.2.9.5. Strategies
  - 10.2.9.6. Financials (Based on Availability)

Product Code: FBI113411

List of Tables

Table 1: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 2: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
Table 3: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 4: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
Table 5: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
Table 6: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 7: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
Table 8: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 9: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
Table 10: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 11: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 12: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
Table 13: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 14: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
Table 15: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
Table 16: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 17: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
Table 18: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 19: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
Table 20: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
Table 21: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 22: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
Table 23: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 24: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

Figure 1: Global mRNA Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
Figure 2: Global mRNA Therapeutics Market Value Share (%), by Type, 2025 & 2034
Figure 3: Global mRNA Therapeutics Market Value Share (%), by Application, 2025 & 2034
Figure 4: Global mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
Figure 5: Global mRNA Therapeutics Market Value (USD billion), by Region, 2025 & 2034
Figure 6: North America mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
Figure 7: North America mRNA Therapeutics Market Value Share (%), by Type, 2025
Figure 8: North America mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
Figure 9: North America mRNA Therapeutics Market Value Share (%), by Application, 2025
Figure 10: North America mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 11: North America mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
Figure 12: North America mRNA Therapeutics Market Value (USD billion), By Country, 2025 & 2034
Figure 13: North America mRNA Therapeutics Market Value Share (%), By Country, 2025
Figure 14: Europe mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
Figure 15: Europe mRNA Therapeutics Market Value Share (%), by Type, 2025
Figure 16: Europe mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
Figure 17: Europe mRNA Therapeutics Market Value Share (%), by Application, 2025
Figure 18: Europe mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 19: Europe mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
Figure 20: Europe mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
Figure 21: Europe mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
Figure 22: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
Figure 23: Asia Pacific mRNA Therapeutics Market Value Share (%), by Type, 2025
Figure 24: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
Figure 25: Asia Pacific mRNA Therapeutics Market Value Share (%), by Application, 2025
Figure 26: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 27: Asia Pacific mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
Figure 28: Asia Pacific mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
Figure 29: Asia Pacific mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
Figure 30: Rest of the World mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
Figure 31: Rest of the World mRNA Therapeutics Market Value Share (%), by Type, 2025
Figure 32: Rest of the World mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
Figure 33: Rest of the World mRNA Therapeutics Market Value Share (%), by Application, 2025
Figure 34: Rest of the World mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 35: Rest of the World mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
Figure 36: Global mRNA Therapeutics Market Share (%), By Company, 2025

mRNA Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

Description

Table of Contents

List of Tables

Growth Factors of mRNA therapeutics Market

Segmentation Analysis

1. Prophylactic (Vaccines)

2. Drugs/Medications

Regional Outlook

Table of Content

1. Introduction

2. Executive Summary

3. Market Dynamics

4. Key Insights

5. Global mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

6. North America mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

7. Europe mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

8. Asia Pacific mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

9. Rest of the World mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

10. Competitive Analysis

List of Tables

List of Figures